- Marinomed to sell Carragelose business to Unither Pharmaceuticals, a leading contract development and manufacturing organization (CDMO) of medical devices and pharmaceutical products
- Proceeds from sale of Carragelose business amounting to up to EUR 20 million to finance restructuring plan, continuation of the Company and investment in Marinosolv platform
- Closing is, among other requirements, subject to the successful completion of the restructuring proceedings and the approval by the shareholders at an extraordinary general meeting
The full press release is available as download here: